Cáncer renal subgrupos de pacientes y poblaciones especiales: ¿qué hemos aprendido? - page 75

PFS:

8.3 mo SU vs 5.6 EV

OS:

31.5 mo SU vs 13.2 EV

Armstrong AJ, et al. Lancet Oncol 2016;17:378‐88

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,65,66,67,68,69,70,71,72,73,74 76,77,78,79,80,81,82,83,84